Leveraging a Safe Balance Between Efficacy and Toxicity in AAV products

Time: 11:30 am
day: Gene Therapy Beyond Rare Diseases Discussion Day

Details:

• Ensuring persistent gene expression and long-term efficacy of AAV drugs
• Strategies to minimize the toxicity of AAV therapies
• Discussing optimal dosage size and vector concentration to avoid toxicity complications

Speakers:

Brian Furmanski Brian Furmanski is the Chief Regulatory Officer at Kriya. Prior to Bian was a Senior Clinical Pharmacology Reviewer at the FDA, investigator in the muscle Read more